PHENDUREN 100
July 1, 2017
PRIMOPRIM 100
July 1, 2017

PHENDUREN 275

£10.00

Nandrolone blend 275 MG

275mg/ml Solution for injection

Clear
SKU: N/A Category:
Description

COMPOSITION
Each ml contains:
Nandrolone decanoate U.S.R 200mg
Nandrolone phenylpropionate B.R 75mg
Oil base q.s.

Read this entire leaflet carefully before you use this medicine.Indicationsand usage:
Phenduren275™ is ind tested for the management of the anaemia of renal insufficiency and has been shown to increase haemoglobin and red cell mass.
Contraindications:
1. Knownhypersensitivitytothedrug.
2. Male patients with carcinoma of the breast or with known or suspected carcinoma of the prostate.
3. Carcinoma of the breast in females with hypercalcemia:
androgenic anabotic steroids may stimulate osteolytic resorption of bones.
4. Pregnancy, because olmascuimisationol the foelus.
5. Nephrosis orthe nephrotic phase of nephritis
6. Patients withseriouscardiac,hepaticor renal disease.
Drug interactions:
Anticoagulants. Anabolic steroids may increase sensitivity to oral anticoagulants. Dosage of the anticoagulant may have to be decreased m order to maintain the prothrombin time at the desired therapeutic level. Patients receiving oral anticoagulant therapy require close monitoring, especially when anabolic steroids are started or stopped Anabolic steroids may decrease levels of thyroxine-binding globuln. resulting in decreased lotal T4 serum levels and increased resin uptake of T3 and T4. Free thyroid hormone levels remamunchanged.
Overdosage:
There have been no reports of acute overdosage with the anabolics.
Adverse reactions:
Hepatic Cholestatic jaundice with, rarefy, hepatic necrosis and death Hepatocellular neophasms and peliosis hepatitis have been reported in association with long-term use of androgenic anabolic steroids, particularly those that are 17-aipha-alkyiated.
Genitourinary System:
In men: Prepubertal: Phallic enlargement and increased frequency of erections.
Postpubertal: Inhibition of testicular (unction, testicular atrophy and oligospermia, impotence, chronic priapism, epididymitis and bladder irntabdity.
In women: Clkoral enlargement, menstrual irregularities.
In both sexes: Increased or decreased libido.
CNS: Habituation, excitation, insomnia, depression.
Gastrointestinal: Nausea, vomiting, diarrhea
Hematologic: Bleeding in patients on concomitant anticoagulant therapy (see Precaution. Drug Interactions).
Breast: Gynecomastia.
Larynx: Deepen mg of the viocem women.
Hair: Hirsutism and male pattern baldness in women.
Skin: Acne (especially in women and prepubertal boys).
Skeletal: Premature closure ol epphyses in children (see Precaution. Pediatric Use)
Fluid and electrolytes: Edema, retention ol serum electrolytes (sodium chloride, potassium phosphate.calcium).
Metabolic endocrine: Decreased glucose tolerance, increased serum levels of low-density lipoproteins and decreased levels of high-den$ity lipoproteins, increased creatine and creatinine excretion, increased serum levels of creatine phosphokinase. Some virilizing changes in women are irreversible even after prompt discontinuance of therapy and are not prevented by concomitant use of estrogens.Precautions:
Phenduren 275™ should be used with caution m patients with any disease, especially cancer of the proslate or breast. 1 rver. heart. Kid ney disease, allergy, enlarged prostate. High dosage, long term use of androgens has been related to liver cancer. This drug should not be used during pregnancy or lactation. Females should be monitored for signs of virilization, such as deepening of the voice, facial hair. acne, menstrual irregularity or clitorai enlargement, consult the doctor promptly if any of i hese sym ptoms occur Use m children should not be recommended due to the possibility this drug may have undesirable effects related lo the growth of the child, a should be used with extreme caution m geriatric men because they are at higher risk tor developing enlarged prostates or prostate cancer when using this medication.
Dosage and adminstration:
Phenduren 275 * is intended only for deep intramuscular injection preferably into the gluteal muscle Dosage should be based on therapeutic response and consideration of the beneM/risk ratio. Duration ol therapy will depend on the response ol the condition and the appearance of adverse reactions, if possible, therapy should be intermittent.
Phenduren 276™ should be regarded as adjunetive therapy and adequate quantiles of nutrients should be consumed in order to obtain maximal therapeutic effects.
Anaemia of renaf disease
A dose ol 50-100 mg per week Phenduren 275™ is recommended lor women and 100-200 mg per week tor men Drug therapy should be discontinued * no hematologic improvement is seen within the first six months. When used in the treatment ol renal insufficiency, adequate iron intake is required lor maximal response For children from 2 to 13 years of age. the average dose is 25-50 mg every3to4weeks
Warnings:
Peliosis hepatitis, a condition n which liver and sometimes splenic tissue is replaced with blood-filled cysts, occurred in patients receiving androgenic anabolic steroids. The condition may not be recognized until life-threatening liver failure or intra-abdommai haemorrhage develops. Lesions completely resolve upon discontinuation. Lnrer ceN tumour, often benign and androgen-dependent but sometimes malignant, have occurred. Drug discontinuation often results in regression or cessation of tumour growth. Hepatic tumours associated with androgens or anabolic steroids may be silent unU hfe-threatenmg, intra-abdominal haemorrhage develops. Blood lipid changes, including decreased HDLand increased LDL. associated with increased nskol atherosclerosis are seen in some patients treated wiih androgens and anabolic steroids
How supplied
Phenduren 275™ is suppled in 1 ml ampoule. Ampoules should be stored at controlled room temperatures below 30*C and protected from light. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Warming and shaking the ampoule should redissolve any crystals that may have formed during storage at temperatures lower than recommended. If it has expiredor is damaged, return it to your pharmacist for disposal.
Abuse in Sports
Abuse of this product in sports is highly discouraged. Thager pharma does not take any responsibility for use of this product for any other purpose. This product should be used under proper medical supervision.
Keep out of the reach and sight of children.
Effect of materials on plants or animals: This product may be harmful to contaminated plant and animal life.
Effect of chemicals on aquatic life: This product may be harmful to aquatic plant and animal life m contaminated bodies of water, especially if released m large quantities

Additional information
Amount

10 х 1ml

Reviews (0)

Reviews

There are no reviews yet.

Be the first to review “PHENDUREN 275”

Your email address will not be published. Required fields are marked *